eligibility_summary
Key eligibility: Adults ≥18, consented, ECOG ≤2, transplant-eligible, measurable DLBCL-spectrum histology after 1 prior chemo-immunotherapy, adequate counts and liver/renal function, pregnancy testing/contraception, archival tissue. Exclude: CNS disease, Richter’s, prior solid organ/HCT, significant cardiac disease/recent MI/CVA, active infection or recent major surgery, HIV/HBV/HCV per criteria, prior anti-CD19/lenalidomide, GI malabsorption/sugar intolerance, VTE without prophylaxis, unresolved toxicity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm salvage trial in transplant-eligible relapsed/refractory large B‑cell lymphoma. Interventions: tafasitamab (IV anti‑CD19, Fc‑engineered monoclonal antibody, drives ADCC/ADCP and direct apoptosis of CD19+ B cells) plus lenalidomide (oral immunomodulatory drug, IMiD, binds cereblon to degrade IKZF1/3, boosts T/NK activation, enhances ADCC, anti‑angiogenic), then tafasitamab + ICE chemotherapy: ifosfamide (alkylating DNA crosslinker), carboplatin (platinum DNA crosslinker), etoposide (topoisomerase II inhibitor). Targets/pathways: CD19 on malignant B cells, immune effector mechanisms (NK/T‑cell activation, antibody‑dependent cytotoxicity/phagocytosis), DNA damage/replication pathways via crosslinking and topo II–mediated double‑strand breaks. Imaging/biopsies/ctDNA used to monitor response.